{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T20:40:56Z","timestamp":1783456856566,"version":"3.55.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12098-021-03824-3","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T14:13:18Z","timestamp":1625148798000},"page":"1209-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Non-GH Agents and Novel Therapeutics in the Management of Short Stature"],"prefix":"10.1007","volume":"88","author":[{"given":"Rita","family":"Saroufim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"Eugster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"3824_CR1","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/MOP.0000000000000505","volume":"29","author":"A Grimberg","year":"2017","unstructured":"Grimberg A, David A. Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence. Curr Opin Pediatr. 2017;29:466\u201371.","journal-title":"Curr Opin Pediatr"},{"key":"3824_CR2","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1542\/peds.2008-1783","volume":"123","author":"J Carel","year":"2009","unstructured":"Carel J, Eugster E, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123:e752\u201362.","journal-title":"Pediatrics"},{"key":"3824_CR3","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jpeds.2015.05.031","volume":"167","author":"E Eugster","year":"2015","unstructured":"Eugster E. The use of gonadotropin-releasing hormone analogs beyond precocious puberty. J Pediatr. 2015;167:481\u20135.","journal-title":"J Pediatr"},{"key":"3824_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1159\/000499929","volume":"28","author":"N Khawaja","year":"2019","unstructured":"Khawaja N, Owaineh H, Batieha A, Frahid O, El-Khateeb M, Ajlouni K. The effect of gonadotropin-releasing hormone analogue on final adult height in children with idiopathic short stature. Med Princ Pract. 2019;28:509\u201316.","journal-title":"Med Princ Pract"},{"key":"3824_CR5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa013555","volume":"348","author":"J Yanovski","year":"2003","unstructured":"Yanovski J, Rose S, Municchi G, et al. Treatment with a luteinizing hormone-releasing hormone agonist in adolescents with short stature. N Engl J Med. 2003;348:908\u201317.","journal-title":"N Engl J Med"},{"key":"3824_CR6","doi-asserted-by":"crossref","unstructured":"Pasquino A, Pucarelli I, Roggini M, et al. Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab. 2000;85:619\u201322.","DOI":"10.1210\/jcem.85.2.6387"},{"key":"3824_CR7","doi-asserted-by":"crossref","unstructured":"Lazar L, Levy S, Oron T, et al. The beneficial effect of combined gh\/gnrha therapy in increasing adult height outcome in children with ISS. J Clin Endocrinol Metab. 2019;104:3287\u201395.","DOI":"10.1210\/jc.2019-00233"},{"key":"3824_CR8","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1530\/EC-18-0137","volume":"7","author":"I Benabbad","year":"2018","unstructured":"Benabbad I, Rosilio M, Tauber M. Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature. Endocr Connect. 2018;7:708\u201318.","journal-title":"Endocr Connect"},{"key":"3824_CR9","doi-asserted-by":"publisher","first-page":"4096","DOI":"10.1210\/jc.2012-1987","volume":"97","author":"A Lem","year":"2012","unstructured":"Lem A, van der Kaay D, de Ridder M, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial. J Clin Endocrinol Metab. 2012;97:4096\u2013105.","journal-title":"J Clin Endocrinol Metab"},{"key":"3824_CR10","doi-asserted-by":"crossref","unstructured":"Van der Steen M, Lem A, van der Kaay D, Hokken-Ko\u00e8elega AC. Puberty and pubertal growth in GH-treated SGA children: effects of 2 years of GnRHa versus No GnRHa. J Clin Endocrinol Metab. 2016;101:2005\u201312.e.","DOI":"10.1210\/jc.2016-1317"},{"key":"3824_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1210\/jc.2009-1577","volume":"95","author":"R Scalco","year":"2010","unstructured":"Scalco R, Melo S, Pugliese-Pires P, et al. Effectiveness of the combined recombinant human growth hormone and gonadotropin-releasing hormone analog therapy in pubertal patients with short stature due to SHOX deficiency. J Clin Endocrinol Metab. 2010;95:328\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"3824_CR12","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1515\/jpem-2019-0105","volume":"32","author":"M Censani","year":"2019","unstructured":"Censani M, Feuer A, Orton S, Askin G, Vogiatzi M. Changes in body mass index in children on gonadotropin-releasing hormone agonist therapy with precocious puberty, early puberty or short stature. J Pediatr Endocrinol Metab. 2019;32:1065\u201370.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3824_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.6065\/apem.2017.22.1.27","volume":"22","author":"J Park","year":"2017","unstructured":"Park J, Hyun KJ. Change in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2017;22:27\u201335.","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"3824_CR14","first-page":"e23085","volume":"13","author":"KS Arani","year":"2015","unstructured":"Arani KS, Heidari F. Gonadotropin-releasing hormone agonist therapy and obesity in girls. Int J Endocrinol Metab. 2015;13:e23085.","journal-title":"Int J Endocrinol Metab"},{"key":"3824_CR15","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jpeds.2013.01.021","volume":"163","author":"D Gillis","year":"2013","unstructured":"Gillis D, Karavani G, Hirsch HJ, Strich D. Time to menarche and final height after histrelin implant treatment for central precocious puberty. J Pediatr. 2013;163:532\u20136.","journal-title":"J Pediatr"},{"key":"3824_CR16","first-page":"275","volume":"63","author":"D Sandberg","year":"2005","unstructured":"Sandberg D, Colsman M. Growth hormone treatment of short stature: status of the quality of life rationale. Horm Res. 2005;63:275\u201383.","journal-title":"Horm Res"},{"key":"3824_CR17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000501336","volume":"91","author":"K Bangalore Krishna","year":"2019","unstructured":"Bangalore Krishna K, Fuqua J, Rogol A, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91:357\u201372.","journal-title":"Horm Res Paediatr"},{"key":"3824_CR18","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","volume":"331","author":"E Smith","year":"1994","unstructured":"Smith E, Boyd J, Frank G, et al. Estrogen resistance caused by a mutation in the estrogen receptor gene in a man. N Engl J Med. 1994;331:1056\u201361.","journal-title":"N Engl J Med"},{"key":"3824_CR19","doi-asserted-by":"crossref","unstructured":"Morishima A, Grumbach M, Simpson E, Fisher C, Qin K. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab. 1995;80:3689\u201398.","DOI":"10.1210\/jcem.80.12.8530621"},{"key":"3824_CR20","doi-asserted-by":"crossref","unstructured":"Lanes R, Gonza\u00b4 lez Brice\u00f1o L. Alternatives in the treatment of short stature. Adv Pediatr. 2017;64:111\u201331.","DOI":"10.1016\/j.yapd.2017.03.004"},{"key":"3824_CR21","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0140-6736(00)04895-9","volume":"357","author":"S Wickman","year":"2001","unstructured":"Wickman S, Sipil\u00e4 I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L. A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet. 2001;357:1743\u20138.","journal-title":"Lancet"},{"key":"3824_CR22","doi-asserted-by":"crossref","unstructured":"Salehpour S, Alipour P, Razzaghy-Azaret M al. A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature. Horm Res Paediatr. 2010;74:428\u201335.","DOI":"10.1159\/000315482"},{"key":"3824_CR23","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1210\/jc.2005-1392","volume":"90","author":"M Hero","year":"2005","unstructured":"Hero M, Norjavaara E, Dunkel L. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab. 2005;90:6396\u2013402.","journal-title":"J Clin Endocrinol Metab"},{"key":"3824_CR24","doi-asserted-by":"crossref","unstructured":"Mauras N, Gonzalez de Pijem L, Hsiang HY, et al. Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years. J Clin Endocrinol Metab. 2008; 93: 823\u201331.","DOI":"10.1210\/jc.2007-1559"},{"key":"3824_CR25","doi-asserted-by":"publisher","first-page":"4984","DOI":"10.1210\/jc.2016-2891","volume":"101","author":"N Mauras","year":"2016","unstructured":"Mauras N, Ross JL, Gagliardi P, et al. Randomized trial of aromatase inhibitors, growth hormone, or combination in pubertal boys with idiopathic, short stature. J Clin Endocrinol Metab. 2016;101:4984\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"3824_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000439338","volume":"30","author":"M Hero","year":"2016","unstructured":"Hero M. Aromatase inhibitors in the treatment of short stature. Endocr Dev. 2016;30:130\u201340.","journal-title":"Endocr Dev"},{"key":"3824_CR27","first-page":"290","volume":"71","author":"M Hero","year":"2009","unstructured":"Hero M, M\u00e4kitie O, Kr\u00f6ger H, et al. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature. Horm Res. 2009;71:290\u20137.","journal-title":"Horm Res"},{"key":"3824_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1530\/eje.1.02226","volume":"155","author":"M Hero","year":"2006","unstructured":"Hero M, Ankarberg-Lindgren C, Taskinen M, Dunkelet L. Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition. Eur J Endocrinol. 2006;155:453\u201360.","journal-title":"Eur J Endocrinol"},{"key":"3824_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/eje.0.1460339","volume":"146","author":"S Wickman","year":"2002","unstructured":"Wickman S, Saukkonen T, Dunkel L. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor. Eur J Endocrinol. 2002;146:339\u201346.","journal-title":"Eur J Endocrinol"},{"key":"3824_CR30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1097\/00006250-199406000-00017","volume":"83","author":"D Kampen","year":"1994","unstructured":"Kampen D, Sherwin B. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979\u201383.","journal-title":"Obstet Gynecol"},{"key":"3824_CR31","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1530\/EJE-10-0040","volume":"163","author":"Hero M, Maury S, Luotoniemi E, Service E, Dunkel L","year":"2010","unstructured":"Hero M, Maury S, Luotoniemi E, Service E, Dunkel L. Cognitive effects of aromatase inhibitor therapy in peripubertal boys. Eur J Endocrinol. 2010;163:149\u201355.","journal-title":"Eur J Endocrinol"},{"key":"3824_CR32","doi-asserted-by":"publisher","unstructured":"McGrath N, O'Grady M. Aromatase inhibitors for short stature in male children and adolescents. Cochrane Database Syst Rev. 2015:CD010888. https:\/\/doi.org\/10.1002\/14651858.CD010888.","DOI":"10.1002\/14651858.CD010888"},{"key":"3824_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/humu.21636","volume":"33","author":"S Foldynova-Trantirkova","year":"2012","unstructured":"Foldynova-Trantirkova S, Wilcox WR, Krejci P. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias. Hum Mutat. 2012;33:29\u201341.","journal-title":"Hum Mutat"},{"key":"3824_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.ajhg.2012.10.014","volume":"91","author":"F Lorget","year":"2012","unstructured":"Lorget F, Kaci N, Peng J, et al. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91:1108\u201314.","journal-title":"Am J Hum Genet"},{"key":"3824_CR35","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/jpet.114.218560","volume":"353","author":"D Wendt","year":"2015","unstructured":"Wendt D, Dvorak-Ewell M, Bullens S, et al. Neutral endopeptidase-resistant C-type natriuretic peptide variant represents a new therapeutic approach for treatment of fibroblast growth factor receptor 3-related dwarfism. J Pharmacol Exp Ther. 2015;353:132\u201349.","journal-title":"J Pharmacol Exp Ther"},{"key":"3824_CR36","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020;396:684\u201392.","journal-title":"Lancet"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-021-03824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-021-03824-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-021-03824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T11:21:13Z","timestamp":1636975273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-021-03824-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3824"],"URL":"https:\/\/doi.org\/10.1007\/s12098-021-03824-3","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"29 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Erica Eugster is the guarantor for this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}